🦠

Infectious Disease

104 drugs in pipeline from 10 companies

104

Drugs in Pipeline

Companies

Upcoming Catalysts

104

Phase 3 Trials

Upcoming Catalysts

AKROPhase 3$1.6T

Efruxifermin Phase 3 Results Expected

Efruxifermin• NASH - Nonalcoholic Steatohepatitis700

Apr 15Estimated

CT.gov

00%

GILDPhase 3$60.0B

✓Positive

PTM B/F/TAF Phase 3 Results Expected

PTM B/F/TAF• HIV-1-infection609

Apr 15Estimated

CT.gov

GILDPhase 3$60.0B

✓Positive

B/F/TAF Phase 3 Results Expected

B/F/TAF• HIV-1-infection609

Apr 15Estimated

CT.gov

GILDPhase 3$60.0B

ISL/LEN Phase 3 Results Expected

ISL/LEN• HIV-1-Infection600

Apr 15Estimated

CT.gov

00%

LPCNPhase 3$16M

Placebo Phase 3 Results Expected

LPCN 1144 Formulation A• Nonalcoholic Steatohepatitis (NASH)80

Apr 15Estimated

CT.gov

00%

SNYPhase 2$115.3B

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 Phase 2 Results Expected

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1• Influenza1,162

Apr 16Estimated

CT.gov

00%

SNYNFPhase 3$114.8B

NVX-CoV2705 Phase 3 Results Expected

NVX-CoV2705• COVID-19676

Apr 16Estimated

CT.gov

00%

SNYPhase 3$115.3B

Low Dose (LD) RSVt vaccine Phase 3 Results Expected

Low Dose (LD) RSVt vaccine• RSV Immunisation947

Apr 17Estimated

CT.gov

00%

View all catalysts

Pipeline by Phase

Phase 3

104

Active Companies

GILD

Gilead Sciences, Inc.

GSK plc

BRISTOL MYERS SQUIBB CO

MERCK

NOVARTIS AG

Novartis AG

PFIZER

Roche Holding AG

Sanofi

Sanofi

Related Conditions

infectiousviralbacterialfungalhivaidshepatitiscovidcoronavirusrsvinfluenzafluantibioticantiviralvaccinesepsistuberculosismalariaherpescmvebv